The drug improvement course of is damaged. On common it takes 10-15 years and $2 billion to carry a drug to market, and almost 90% of candidates fail alongside the best way. Enter AI, a know-how that’s mastered essentially the most refined video games we have now. It might even predict how proteins fold, and that’s earlier than it grew to become mainstream. It is smart that we should always use AI to carry medication to market faster and at a decrease value. So why is it that AI drug discovery firms have largely did not seize all these grand aspirations?
We’ve been carefully following plenty of AI drug discovery firms, one being Schrödinger $SDGR. Right now we’re going to revisit previous considerations to see if issues are lastly wanting up for a corporation that must be making hay whereas the solar shines.
A Useless Cat Bounce?
We spend money on firms, not shares, but it surely’s exhausting to not discover simply how dreadfully Schrödinger’s inventory has carried out over the previous 5 years, having misplaced 88% of its worth. The result’s that they’re now within the “demise zone” with a market cap slightly below $1 billion. Whereas the inventory worth reacted positively to their current earnings report and guarantees of stronger-than-expected development, that will simply be a useless (Schrödinger’s) cat bounce. Their enterprise, whereas rising, is on a trajectory that appears problematic, and the inventory worth displays that.
